<DOC>
	<DOCNO>NCT02544243</DOCNO>
	<brief_summary>Development active second-line treatment option metastatic breast cancer patient previously pre-treated anthracyclines taxanes neoadjuvant , adjuvant palliative settings.For randomisation arm , 100 patient include . The trial perform 2-stage phase II study accord optimal design Simon overall response rate primary objective . Study Design : Arm A Vinorelbine 25 mg/m2 d1 , 8 ; Gemcitabine 1000 mg/m2 d1 , 8 q 3 week Arm B Vinorelbine 25 mg/m2 d1 , 8 ; Cisplatin 25 mg/m2 d1 , 2,3 q 3 week</brief_summary>
	<brief_title>Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically confirm metastatic breast cancer All patient require give write informed consent To receive previous treatment anthracyclines taxanes Previous radiotherapy allow , whenever radiate area disease location At least 4 week since last previous antineoplastic treatment Patients must recover previous toxicity Karnofsky Performance status &gt; = 70 % Adequate hematological , renal , cardiac hepatic function Life expectancy least 12 week Patients able comply receive adequate followup Only bone metastasis Active infection Previous treatment one study drug Application cytotoxic chemotherapy Insufficient renal function ( creatinine clearance &lt; 60ml/min ) Clinically unstable brain metastasis Pregnancy lactation Other primary malignancy ( carcinomainsitu cervix adequately treat basal cell cancer skin ) Abnormal liver function ( bilirubin &gt; 2.0fold upper normal limit ( UNL ) ; Alanine aminotransferase aspartate aminotransferase &gt; 2.5fold UNL ) . In patient hepatic metastasis , value Alanine aminotransferase aspartate aminotransferase 5fold UNL permit Males Second malignancy ( except cervix carcinoma situ skin carcinoma melanoma adequate treatment ) . Previous malignancy allow diseasefree survival superior 5 year , except renal carcinoma melanoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>